← Library
Sold as a supplement, not an FDA-approved drug. This page is educational information only, not medical advice.
IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Lactotripeptides

Supplement

Milk-derived bioactive tripeptides

Also known as: IPP, VPP, casein tripeptides

Evidence score
29/ 100
Thin evidence

Very thin human evidence

  • Regulatory standing. Sold as a supplement, not an approved drug
  • Limited human data. Some human data exists, not conclusive
  • No registered human trials. Nothing registered on ClinicalTrials.gov
  • No sources. Nothing cited to verify

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Lactotripeptides are short peptides, mainly isoleucine-proline-proline (IPP) and valine-proline-proline (VPP), produced when milk casein is fermented or enzymatically broken down. They are sold as dietary supplements and in some functional foods. They are thought to mildly inhibit angiotensin-converting enzyme (ACE), which plays a role in blood pressure regulation.

What the evidence shows

Automatic summaryLimited human data

A number of small human studies and meta-analyses have looked at modest blood pressure effects, with mixed results that vary by population and study design, and no registered trials were found in the provided data. They are not FDA-approved for any condition, and any benefit remains uncertain.

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

0registered studies
Nonemost advanced phase
0completed (sample)
0recruiting (sample)

Published literature

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.